Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR $200, AEP $139, INTU $430, BCSF $13, GEMI $6, VEEV $275.
Stocks · News reference
8-K filing — ArriVent BioPharma, Inc. (AVBP)
Filed: 2026-08-12 AccNo: 0001104659-26-094869 Size: 305 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $47
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $44 to $47.
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.
Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target
Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.